ANALYZING DALFAMPRIDINE'S POTENTIAL FOR PROLONGED RELEASE AS A MATRIX TABLET USING VARIOUS GRADES OF HPMC AND EUDRAGIT

Present studies aimed to formulate a once-daily sustained-release matrix tablet of Dalfampridine to reduce the frequency of administration and improve patient compliance. Multiple sclerosis patients who have trouble walking can benefit from dalfampridine. Dalfampridine is taken orally twice daily in doses of 10 mg, with a plasma half-life of 5.2 to 6.5 hours. A once-daily sustained-release version of dalfampridine is preferred to lessen administration frequency and boost patient compliance. BCS Class I chemical with high solubility, high permeability, and pH-independent solubility. Using hydrophilic synthetic polymers like hydroxyl propyl methyl cellulose (HPMC K4M & HPMC K15M) and hydrophobic synthetic polymers like Eudragit RSPO and RLPO, the current work sought to evaluate and improve sustained released Dalfampridine matrix tablets. To improve the release rate for a once-daily drug, a matrix tablet containing dalfampridine was created using the wet granulation process at various ratios of HPMC and Eudragit. Utilizing a USP type-II paddle type eight station dissolving device, an in vitro release investigation was carried out. To confirm the drug's compatibility with polymers, FTIR and DSC studies were conducted. Different pre- and post-compression characterizations of the tablet were conducted, and the results complied with pharmacopeia requirements. Accelerated stability experiments were done to confirm the stability of the dosage formulations.

Key Words: Sustained release tablet, Dalfampridine, Matrix tablets, HPMC, Eudragit.